# Diabetes Hub Monitor Report — 2026-04-22

**Scan time:** 2026-04-22 (automated run)
**Previous monitor report:** 2026-04-21
**Compared snapshots:** 2026-04-21 → 2026-04-22 (daily); 2026-04-15 → 2026-04-22 (weekly)

---

## File System Status

All expected monitor inputs are present and fresh.

| File | Last Modified | Age (days) | Status |
|------|---------------|-----------|--------|
| hub_monitor_report.md | 2026-04-22 07:05 | 0.0 | Fresh |
| clinical_trials_latest.json | 2026-04-22 07:04 | 0.0 | Fresh |
| pubmed_recent_latest.json | 2026-04-22 07:05 | 0.0 | Fresh |
| literature_gap_data.json | 2026-04-20 15:35 | 1.7 | Fresh |
| literature_gap_report.md | 2026-04-21 08:13 | 1.0 | Fresh |

Hub monitor scan: 4 new files, 37 modified files, 0 removed since 2026-04-21. Total tracked = 743 files. The scan flagged 483 result files older than 14 days (pre-existing baseline data); no action required unless a specific file is needed for an active analysis.

---

## Clinical Trial Changes

**Snapshot:** 768 total diabetes trials across 5 categories. 263 RECRUITING, 261 COMPLETED, 130 NOT_YET_RECRUITING, 109 ACTIVE_NOT_RECRUITING, 5 ENROLLING_BY_INVITATION. 116 Phase 3 trials (43 currently recruiting).

### Daily diff (2026-04-21 → 2026-04-22)

- **New trials:** 1
  - NCT03898206 — "Effects of Breaking up Prolonged Sitting on Postprandial Cardiometabolic Disease Risk Markers in South Asians" (University of Bedfordshire). Status: COMPLETED. Category: Diabetes Recently Completed with Results. Low priority — behavioral substudy, not interventional.
- **Status changes:** 0
- **New results posted:** 0
- **Removed:** 0

### Weekly diff (2026-04-15 → 2026-04-22)

- **8 new trials added in past 7 days** (mostly Phase 4/NA registrations of older studies back-filled to ClinicalTrials.gov; e.g. NCT05727579 Phase 4 ertugliflozin/sodium-intake study, NCT07536516 retinal oxygen extraction). None are high-priority Phase 3 industry programs.
- **3 status changes in past 7 days** (not individually flagged by daily diff — routine progression).

### Key Phase 3 programs — current status

Priorities per RESEARCH_DOCTRINE Tier 1 watchlist:

| Sponsor / Therapy | Trial(s) | Status | Note |
|---|---|---|---|
| Vertex / zimislecel (VX-880) | NCT04786262, NCT06832410 | RECRUITING (Phase 3) | FORWARD-101 pivotal. Regulatory submission expected 2026. No new results posted this week. |
| Vertex / VX-264 (encapsulated) | NCT05791201 | ACTIVE_NOT_RECRUITING | Phase 1/2. |
| Eli Lilly / baricitinib (LY3009104) | NCT07222332, NCT07222137 | RECRUITING (Phase 3) | BARICADE-PRESERVE (new-onset T1D) and BARICADE-DELAY (Stage 1/2 T1D). |
| Eli Lilly / tirzepatide in T1D | NCT06914895, NCT06962280 | ACTIVE_NOT_RECRUITING (Phase 3) | T1D-with-obesity programs. |
| Eli Lilly / retatrutide | NCT05929079, NCT06297603, NCT06260722 | ACTIVE_NOT_RECRUITING (Phase 3) | TRANSCEND-T2D series. |
| Eli Lilly / orforglipron | NCT06972472, NCT06993792 | ACTIVE_NOT_RECRUITING / RECRUITING (Phase 3) | FDA approved as Foundayo for weight loss on 2026-04-01 (see Breaking News). |
| Novo Nordisk / CagriSema | NCT06534411 | ACTIVE_NOT_RECRUITING (Phase 3) | Blood-sugar + weight outcomes. |
| Novo Nordisk / insulin icodec | NCT07076199 | RECRUITING (Phase 3) | Weekly basal — FDA approved for T2D in March 2026 (see Breaking News). |
| Sanofi + various / teplizumab | NCT05757713 (Phase 4 pediatric), NCT07216391 (Phase 2 platform vs ATG) | Active | Stage 3 preservation and Stage 2 delay contexts. |

No Phase 3 trial in the watchlist posted new results in the past 7 days.

---

## PubMed Highlights

**Snapshot:** 147 unique papers across 16 alert domains (up from 139 yesterday, 127 one week ago). 30 new PMIDs since 2026-04-21; 98 new PMIDs since 2026-04-15.

### Cross-Domain Papers (highest priority)

Eight papers appear in 2+ alert domains. Two are new today:

- **[PMID 42008388]** *Harnessing Herbal Power: A Systematic Review of Phytopharmaceuticals in Type 2 Diabetes Management.* — T2D GLP-1 New ∩ Diabetes Microbiome. Review-level (Evidence: low-grade).
- **[PMID 42013790]** *Serum IL-34 and IL-17A as novel biomarkers for diabetic retinopathy in type 2 diabetes.* — Diabetes Biomarker ∩ Diabetes Complications New. Cross-sectional (Evidence: moderate for association, not causation).

Six other standing cross-domain papers worth keeping on the reading list:

- [PMID 41995155] *Engineering immune-evasive islet replacement: cell-intrinsic and peri-graft strategies.* — T1D Stem Cell Cure ∩ Gene Therapy. Directly relevant to Vertex VX-264 / hypoimmune islet programs.
- [PMID 42002040] *Ketosis-Prone Type 2 Diabetes Mellitus: Three Decades of Clinical, Pathophysiologic, and Therapeutic Advances.* — T2D Remission ∩ LADA New Research. Relevant to LADA mis-diagnosis gap (Tier-2 focus).
- [PMID 41997446] *GIPR:GCGR co-agonism restores normal weight in obese rodents.* — T2D Remission ∩ Key Therapy: retatrutide. Mechanistic support for retatrutide class (Evidence: preclinical only).
- [PMID 42007354] *Development and internal validation of an interpretable ML model for prediction…* — Diabetes AI/ML ∩ Diabetes Biomarker. Relevant to Tier-1 Multi-Omics Biomarker Integration.
- [PMID 42003658] *New Horizons in Metabolic Health: Unveiling the Future of Drug Discovery and Development.* — Microbiome ∩ Gene Therapy ∩ dapagliflozin. Opinion/review.
- [PMID 41986815] *Multi-tissue multi-omics integration reveals tissue-specific pathways, gene networks…* — Drug Repurpose ∩ Multi-Omics. Relevant to Tier-1 Drug Repurposing Computational Screening.

### Key therapy mentions in recent literature

- **orforglipron:** 3 papers in past 30 days (PMIDs 41994902 — bioequivalence PK study in *Diabetes, Obesity & Metabolism*; 41984238 — methodology critique in *Acta diabetologica*; 41498807 — GRADE-assessed review). Publication activity has risen alongside the 2026-04-01 FDA approval.
- **retatrutide:** 1 narrative review (PMID 41785010, *Expert Review of Clinical Pharmacology*).
- **teplizumab:** 1 paper on personalized medicine heterogeneity (PMID 41913320, *Diabetes, Obesity & Metabolism*).
- **baricitinib:** 1 hit via domain alert; no stand-alone mechanism paper this week.
- **zimislecel, CagriSema, icodec:** 0 papers in the 30-day lookback window — continue passive monitoring.
- **dapagliflozin:** 32 raw hits (5 unique papers after de-dup) — elevated, consistent with the 2026-04-07 generic launch.

### Volume trend

Publication flow is slightly above baseline (147 vs. 127 seven days ago, +15.7%). LADA New Research and Epigenetics remain the thinnest domains (5 and 8 papers respectively). GLP-1 Pharmacogenomics produced only 1 paper — an Evidence Level 3 gap worth monitoring as pharmacogenomics + GLP-1 intersects both Tier-1 multi-omics and the RESEARCH_DOCTRINE equity focus.

---

## Gap Analysis Summary

Source: `literature_gap_data.json` (generated 2026-04-20) and `literature_gap_report.md` (2026-04-21). 435 domain-pairs scored; Gap Score range 0–100.

### Top 5 meaningful under-researched intersections

All top-5 classified intersections carry gap scores of 100.0 (joint publications at or near zero vs. substantial individual-domain activity). Per the doctrine, these are **BRONZE-validated** preliminary signals — single analytical source, pending expert confirmation.

| Rank | Intersection | Joint Pubs | Rationale / Tier-1 alignment |
|------|--------------|------------|-------------------------------|
| 1 | Beta Cell Regen ∩ Health Equity | 0 | Access equity for emerging cell therapies is absent from the literature. Aligns with Tier-1 Clinical Trial Intelligence and the doctrine's equity imperative. |
| 2 | Insulin Resistance ∩ Islet Transplant | 1 | Insulin resistance in graft recipients affects graft survival but is barely studied. Aligns with Tier-1 Multi-Omics Biomarker Integration (cross-tissue signaling) and Drug Repurposing. |
| 3 | Islet Transplant ∩ Drug Repurposing | 0 | Existing immunosuppressants as islet-protective agents have not been computationally screened. Direct Tier-1 Drug Repurposing Screening opportunity. |
| 4 | Islet Transplant ∩ Health Equity | 0 | Islet transplant access limited to select centers; no equity analysis exists. |
| 5 | Gene Therapy ∩ LADA | 0 | LADA's autoimmune mechanism is a plausible gene-therapy target; no crossover work. LADA alignment with Tier-2 focus in doctrine. |

Six of the top seven meaningful gaps involve either Islet Transplant (4 gaps) or Health Equity (5 gaps), reinforcing that **equity-weighted analysis of islet-transplant therapies is the single highest-leverage computational contribution the hub could make**.

---

## Breaking News (past 7 days, web-checked)

- **FDA approval — Foundayo (orforglipron), 2026-04-01 (within past 7 days at time of last check; now 21 days old):** First oral GLP-1 for weight loss without food/water restrictions. Lilly has submitted for T2D in 40+ countries. Tracked in hub via NCT06972472 / NCT06993792.
- **FDA approval — first generic dapagliflozin, 2026-04-07:** SGLT2 inhibitor for T2D HF hospitalization risk reduction and glycemic control. Expected to drive downward pricing pressure on SGLT2 class — relevant to Tier-1 Drug Repurposing (cost considerations) and Health Equity analyses.
- **FDA approval — once-weekly basal insulin (insulin icodec, Novo Nordisk), March 2026:** For adults with T2D. Corresponding Phase 3 trial NCT07076199 still recruiting in the hub snapshot.
- **Vertex zimislecel (VX-880) Phase 3:** No new Phase 3 results publicly disclosed in the past 7 days. Regulatory submission still expected in 2026. Phase 1/2 results at ADA 2025 (10/12 insulin-independent) remain the most recent efficacy data.

No new Phase 3 read-outs, no unexpected safety signals, no major negative trials reported in the 7-day window.

---

## Recommended Actions

1. **Add two cross-domain papers to the reading queue:** PMID 42008388 (phytopharmaceuticals/microbiome review) and PMID 42013790 (IL-34/IL-17A retinopathy biomarkers). Route the biomarker paper to the Multi-Omics Biomarker pipeline (Tier 1).
2. **Update the Clinical Trials tracker** to capture the 2026-04-01 Foundayo/orforglipron FDA approval and 2026-04-07 dapagliflozin generic approval as regulatory events, even though individual trial status did not change. Consider a `regulatory_events` column in `Diabetes_Research_Tracker.xlsx`.
3. **Scope a Tier-1 contribution on equity-weighted islet-transplant analyses.** The gap report's top 7 intersections cluster tightly around Islet Transplant + Health Equity + Drug Repurposing — the intersection of three Tier-1 doctrine areas. Draft a research plan comparable to `research_plan_islet_drug_repurposing.md`.
4. **Refresh literature_gap_data.json** within the next 7 days (currently 1.7 days old — no action needed today, but flag in next week's run).
5. **No script re-runs required today** — baseline_clinical_trials.py, baseline_pubmed_alerts.py, project1_literature_gap_analysis.py, and hub_monitor.py all produced fresh outputs in the past 48 hours.
6. **Continue passive monitoring of zimislecel, CagriSema, and icodec** PubMed publication activity. A Phase 3 readout for zimislecel is expected in 2026 per Vertex guidance.

---

*Generated by automated hub monitor — 2026-04-22. Evidence levels follow RESEARCH_DOCTRINE.md conventions; gap analyses are BRONZE-validated pending expert review.*

## Sources

- [Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the ADA 85th Scientific Sessions](https://news.vrtx.com/news-releases/news-release-details/vertex-presents-positive-data-zimislecel-type-1-diabetes)
- [FDA Approves First Generic Dapagliflozin Tablets](https://www.fda.gov/drugs/drug-alerts-and-statements/fda-approves-first-generic-dapagliflozin-tablets)
- [FDA approves Lilly's Foundayo (orforglipron)](https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill)
- [FDA approves once-weekly basal insulin for adults with type 2 diabetes (Healio)](https://www.healio.com/news/endocrinology/20260327/fda-approves-onceweekly-basal-insulin-for-adults-with-type-2-diabetes)
- [2025 Top T1D advances: Full speed ahead — Breakthrough T1D](https://www.breakthrought1d.org/news-and-updates/2025-top-t1d-advances-full-speed-ahead/)
